#MEDMASTODON
"The right drug for the right patient" -- the promise of personalized medicine

... but I'm not sure that the study methods are sufficient to justify the conclusions. The reason I'm thankful for peer review.

CD5 Gene Signature Identifies Diffuse Large B-Cell #Lymphomas Sensitive to Bruton's Tyrosine Kinase (BTK) Inhibition

https://pubmed.ncbi.nlm.nih.gov/38079587/

#Cancer #fedscience
#ClinicalResearch #Oncology #Medicine #lymsm @[email protected]

#MEDMASTODON

Interest, attitudes, and participation in clinical trials among #lymphoma #patients with online access

Authors: K. Schwartz | Advisors to Patients Against Lymphoma

https://ascopubs.org/doi/abs/10.1200/jco.2009.27.15_suppl.e19514

#Cancer #fedscience
#ClinicalResearch #Oncology #Medicine #lymsm @[email protected]

#MEDMASTODON

Getting the dosing right in combination therapy is a challenge but it can pay off for some patients taking part in trials:

Phase I study of bendamustine, rituximab, ibrutinib, and ramped up dosing of venetoclax in relapsed, refractory mantle cell #lymphoma

#Cancer #fedscience
#ClinicalResearch #Oncology #Medicine #lymsm @[email protected]

Minimal Residual Disease (MRD) Status Predicts Outcome in Patients With Previously Untreated Follicular #Lymphoma

Just saying: Validating MRD as a surrogate endpoint - predicting living longer or better (clinical benefit) is needed

... as the standard time to event endpoints (PFS, survival) take many many years to assess for indolent (slow growing) #cancer.

https://pubmed.ncbi.nlm.nih.gov/38096461/

#MEDMASTODON #lymphoma #Cancer #fedscience
#ClinicalResearch #Oncology #Medicine #lymsm @[email protected]

#MEDMASTODON #lymphoma #Cancer #fedscience
#ClinicalResearch #Oncology #Medicine #lymsm @[email protected]

Tumor Heterogeneity (difference in features and genetic drivers within the same tumor) is not widely appreciated by the lay public - a reason cure remain a challenging treatment goal despite the era of "precision medicine."

Tumor heterogeneity and immune-evasive T follicular cell lymphoma phenotypes at single-cell resolution

https://pubmed.ncbi.nlm.nih.gov/38012392/

Three-Year Follow-Up

Axicabtagene Ciloleucel (CAR T-cell therapy) in Relapsed/Refractory Indolent b-cell Lymphoma (ZUMA-5)

#MEDMASTODON #lymphoma #Cancer #fedscience
#ClinicalResearch #Oncology #Medicine #lymsm @[email protected]

https://pubmed.ncbi.nlm.nih.gov/37879047/

Interim results:

Testing CAR T-cells and Time-Limited Ibrutinib for Relapsed/Refractory Mantle Cell #Lymphoma: Phase II TARMAC Study

#MEDMASTODON #lymphoma #Cancer #fedscience
#ClinicalResearch #Oncology #Medicine #lymsm @[email protected]

https://pubmed.ncbi.nlm.nih.gov/37883795/

Dose-finding study of rituximab, lenalidomide, and ibrutinib (R2I) in relapsed/refractory mantle cell #lymphoma

Gives hope, but be aware there are many issues (too numerous to mention in a toot) with small single-arm studies, such as how many were relapsed versus refractory, and Quality of Life while on continuous treatment. Let's hope the study team confirms with a larger controlled study.

#MEDMASTODON #lymphoma #Cancer #fedscience
#ClinicalResearch #Oncology #Medicine #lymsm @[email protected]

Tafasitamab (cd19 mab) and lenalidomide in large B cell #lymphoma: real-world outcomes in a multicenter retrospective study (abstract only.)

How to reconcile retrospective with prospective study findings - poor versus good respectively?

Selection bias in prospective studies comes to mind -- participants younger than the median age of the afflicted patient population.

#MEDMASTODON #lymphoma #Cancer #fedscience
#ClinicalResearch #Oncology #Medicine #lymsm @[email protected]

Very low-dose radiotherapy for extranodal marginal zone #lymphoma of bronchus-associated lymphoid tissue

https://pubmed.ncbi.nlm.nih.gov/37706509/

Me: small sample, still, will this be offered as a choice by oncologists who may not be licensed to administer it?

#MEDMASTODON #lymphoma #Cancer #fedscience
#ClinicalResearch #Oncology #Medicine #lymsm @[email protected]